Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Red Crescent: More than 100,000 civilian structures damaged in Iran - 2The Beginning Of The End For Fossil Fuels Can Start In Colombia
- 3Photos: Presidential turkey pardons — a look back
- 4Rick Steves Recommends This German Town's Castle Hotel With Rhine River Views
- 5Who was Haytham Ali Tabatabai, Hezbollah's military leader killed by Israel?
- Artemis II astronauts arrive in Florida to prepare for launch to the moon
- Slovakia rejects EU call to scrap higher fuel prices for foreign cars
- Dark matter obeys gravity after all — could that rule out a 5th fundamental force in the universe?
- A NASA spacecraft orbiting Mars may be dead
- Born under fire: MDA delivers baby in Jerusalem minutes before rushing to shelter
- Israel says it killed armed Hamas 'terrorists' in Gaza
- Toyota’s Next Big Sports Car Might Apparently Be a Turbocharged All-Paw Beast
- Tech for Efficiency: Applications and Apparatuses to Accomplish More
- Exploring Being a parent: A Survey of \Bits of knowledge and Guidance for Guardians\ Nurturing Book
